Biotech developing apitegromab, a muscle-growth-promoting myostatin inhibitor for spinal muscular atrophy and other conditions.
Biotech developing apitegromab, a muscle-growth-promoting myostatin inhibitor for spinal muscular atrophy and other conditions.
Has no approved product yet, so it is funded by money raised from investors rather than sales. Any future income would come from selling apitegromab as an add-on to existing spinal muscular atrophy treatments, which work on the nerve cells while apitegromab targets muscle.
Moat: narrow (IP / patents). A selective myostatin-pathway inhibitor differentiated by targeting muscle growth alongside SMA gene therapies.
Headquarters: Cambridge, Massachusetts, US · Founded: 2012 · Employees: 289
Size Scholar Rock (SRRK) is a United States Health Care company (Biotechnology) with a market value of $5.86B, the 1068th largest of 3,085 United States companies the cockpit tracks. Shares closed at $48.00 on 18 Nov 2026.
Performance Over six months the shares fell 0.8%, against -3.5% for the median peer and -2.2% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.
Growth The operating margin is -71,732.3% (peer median -15.6%).
Valuation It trades at 9,900.4× enterprise value to sales against a peer median of 11.3× (most expensive of 16).
Short interest Short interest is 19.3% of the free float (30 Oct 2026).
Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $570,000 | $0 | $0 | $0 | $33.2M |
| Revenue growth | — | — | — | -100% | — |
| Gross profit | -$753,000 | -$1.66M | -$1.94M | -$2.84M | $23.3M |
| EBITDA | -$408M | -$383M | -$250M | -$168M | -$124M |
| Net income | -$414M | -$378M | -$246M | -$166M | -$135M |
| Free cash flow | -$310M | -$301M | -$201M | -$145M | -$134M |
| Capital expenditure | $202,000 | $602,000 | $98,000 | $71,000 | $1.06M |
| Total debt | $203M | $109M | $65.1M | $61.8M | $69.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Scholar Rock SRRK | $5.86B | -1% | n/a | -71,732% | 9,900.4× | n/a |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 6.2× | 1.6% |
| Roche RO.SW | $381B | +21% | -1% | 31% | 5.7× | 1.7% |
| Biogen BIIB | $37.2B | +34% | +2% | 17% | 4.4× | 10.1% |
| Biohaven BHVN | $1.95B | +46% | n/a | n/a | n/a | n/a |
| Regeneron Pharmaceuticals REGN | $97.8B | +46% | +19% | 30% | 5.4× | -1.1% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 15.6× | 6.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SRRK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +16.1% | -7.1% | 4th highest of 21 |
| 6-month return | -0.8% | -3.5% | 9th highest of 21 |
| Distance from 52-week high | -22.3% | -33.1% | 6th highest of 21 |
| Operating margin | -71,732.3% | -15.6% | lowest of 16 |
| EV / Sales | 9,900.4× | 11.3× | most expensive of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Scholar Rock SRRK | United States | $5.86B | -1% | n/a | -71,732% | 9,900.4× | n/a | n/a |
| Arrowhead Pharmaceuticals ARWR | United States | $6.09B | -44% | -46% | -157% | 14.0× | n/a | n/a |
| Caris Life Sciences CAI | United States | $5.59B | +24% | +61% | 13% | 5.0× | 18.2% | +61.5% |
| Anthem Biosciences ANTHEM.NS | India | $5.51B | +16% | -1% | 35% | 24.9× | 36.9% | +26.2% |
| Kodiak Sciences KOD | United States | $6.40B | +170% | n/a | n/a | n/a | n/a | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.28B | -1% | -28% | -210% | 5.3× | -6.5% | -10.0% |
| Immunovant IMVT | United States | $6.86B | -7% | n/a | n/a | n/a | n/a | n/a |
| Hangzhou Tigermed Consulting 300347.SZ | China | $4.88B | -2% | +16% | 10% | 4.8× | 25.9% | +16.4% |
| Axsome Therapeutics AXSM | United States | $7.05B | -42% | +54% | -19% | 8.0× | n/a | n/a |
| Cogent Biosciences COGT | United States | $4.84B | -16% | n/a | n/a | n/a | n/a | n/a |
| CG Oncology CGON | United States | $7.15B | +24% | +184% | -4,294% | 1,000.7× | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.73B | -5% | -12% | -8,684% | 1,432.1× | n/a | n/a |
| Adaptive Biotechnologies ADPT | United States | $4.61B | +104% | +18% | -16% | 15.8× | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.57B | -15% | -22% | 17% | 5.4× | n/a | n/a |
| 10x Genomics TXG | United States | $7.51B | +138% | -4% | -11% | 11.3× | 47.2% | +16.6% |
| Edgewise Therapeutics EWTX | United States | $4.53B | +26% | n/a | n/a | n/a | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.52B | -13% | -18% | -1% | 2.8× | 32.4% | +7.1% |
| Twist Bioscience TWST | United States | $7.93B | +117% | +22% | -29% | 16.2× | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.28B | -31% | +102% | 61% | 0.9× | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.20B | -43% | +8% | -35% | 12.7× | n/a | n/a |
| Summit Therapeutics SMMT | United States | $8.40B | -41% | n/a | n/a | n/a | n/a | n/a |